Aptinyx, which is developing therapeutics for neurological disorders, filed on Wednesday with the SEC to raise up to $80 million in an initial public offering.
The Evanston, IL-based company was founded in 2015 and booked $6 million in sales for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol APTX. Aptinyx filed confidentially on March 30, 2018. J.P. Morgan, Cowen & Company, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
